Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Updates from the ACR Insurance Subcommittee Chair

Rebecca Shepherd, MD, MBA, FACR, FACP  |  September 25, 2023

The Insurance Subcommittee (ISC) of the ACR Committee on Rheumatologic Care has been very active recently, advocating to payers on behalf of our colleagues and the College. I’d like to share an update about several of the issues this group has been working on.

Blue Cross NC Autoimmune Pathways Program

Dr. Shepherd

Blue Cross NC, in partnership with Outcomes Matter Innovations (OMI), introduced the Autoimmune Pathways Program with the stated goal of reducing spending on specialty drugs. The initial iteration of the program achieved these savings by paying physicians to delay the introduction of a biologic or to initiate tapering or so-called drug holidays for patients who are in remission or show low disease activity. The ACR shared significant concerns about the ethics of this program and potential harm to patients’ access to treatment. After conversations with the ACR, Blue Cross NC and OMI have committed to reworking some of the more controversial aspects of the program. The ACR will continue to monitor this evolving program and advocate for fair and transparent policies that protect patients’ access to biologic therapies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Regence BlueShield LevelRx Program

Regence BlueShield, a payer operating in Idaho, Oregon, Utah and Washington, recently introduced the LevelRx program, creating a new specialty medication provider network to be administered by Prime Therapeutics. According to Regence, practices will still be able to directly source drugs for in-office administration; however, they will be required to sign a new contract covering reimbursement for both the drugs and administration. Practices that do not join the new network by Jan. 1, 2024, will be considered out of network with Regence BlueShield and required to obtain drugs through an approved specialty pharmacy.

The ACR sent a letter and spoke with Regence leadership, detailing our concerns about the increased administrative burden on practices and uncertainty around reimbursement rates moving forward. We are also working with local members and state societies to provide additional resources and coordinate ongoing advocacy efforts.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Aetna Coverage for Ultrasound

It was brought to the ISC’s attention that Aetna’s policy on ultrasound is overly restrictive, labeling ultrasound guidance to be “of no proven benefit” for numerous procedures that utilize musculoskeletal ultrasound (MSUS). The ACR sent a letter to Aetna outlining our concerns; we also joined a multispecialty sign-on letter that was led by the American Institute of Ultrasound in Medicine (AIUM). As a result of these letters and subsequent conversations with Aetna’s leadership, the payer has committed to considering the additional data during an internal policy review in October.

Page: 1 2 | Single Page
Share: 

Filed under:Billing/CodingPractice Management Tagged with:ACR Insurance Subcommittee (ISC)Musculoskeletal Ultrasoundspecialty drug acquisition

Related Articles

    New Wins, Ongoing Challenges for ACR Insurance Subcommittee

    July 3, 2019

    Corrections to reimbursement system errors with Aetna and a Medicare contractor demonstrate the latest wins for all providers by the ACR’s Insurance Subcommittee. But the committee remains hard at work advocating for rheumatologists on several fronts.

    Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee

    November 5, 2018

    Both private and academic rheumatology practices face payer challenges that put the health of their patients and their practices at risk. To make sure the rheumatologist perspective is heard by payers, “the ACR’s Insurance Subcommittee (ISC) serves as the interface between payers and our members and ACR colleagues,” explains Sean Fahey, MD, a rheumatologist in…

    ACR Insurance Subcommittee Chair Encourages Member Engagement

    January 20, 2022

    Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.

    Practice Page: The ACR’s Insurance Subcommittee Facilitates Better Communication With Health Insurers for Rheumatology Practices

    June 1, 2013

    Committee is working to develop policy and programs to help ACR members deal with the administrative requirements of health insurance plans

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences